Clinical Trials
55 trialsTesting the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
National Cancer Institute (NCI)
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
National Cancer Institute (NCI)
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
National Cancer Institute (NCI)
Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
National Institutes of Health Clinical Center (CC)
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
National Institutes of Health Clinical Center (CC)
Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
National Cancer Institute (NCI)
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
National Cancer Institute (NCI)
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
National Cancer Institute (NCI)
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
National Cancer Institute (NCI)
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer
National Cancer Institute (NCI)
Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver
National Cancer Institute (NCI)
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Stage III Colon Cancer
National Cancer Institute (NCI)
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
National Cancer Institute (NCI)
S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer
National Cancer Institute (NCI)
Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma
National Cancer Institute (NCI)
Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer
National Cancer Institute (NCI)
Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
National Cancer Institute (NCI)
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
National Cancer Institute (NCI)
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2
National Cancer Institute (NCI)
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
National Cancer Institute (NCI)
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
National Cancer Institute (NCI)
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
National Institutes of Health Clinical Center (CC)
Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer
National Cancer Institute (NCI)
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
National Cancer Institute (NCI)
Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)